AN1 — Anagenics Income Statement
0.000.00%
Consumer DefensivesHighly SpeculativeMicro Cap
Annual income statement for Anagenics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
R2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.34 | 5.82 | 6.95 | 9.11 | 10.8 |
Cost of Revenue | |||||
Gross Profit | 4.85 | 3.7 | 3.8 | 4.41 | 4.36 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11.5 | 9.52 | 8.54 | 10.8 | 18 |
Operating Profit | -4.2 | -3.71 | -1.6 | -1.7 | -7.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.27 | -3.76 | -1.64 | -1.73 | -7.28 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.36 | -3.8 | -1.64 | -1.74 | -7.28 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -4.91 | -3.39 | -3.65 | -2.67 | -7.49 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.91 | -3.39 | -3.65 | -2.67 | -7.49 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.038 | -0.023 | -0.008 | -0.006 | -0.01 |